Evorpacept

Generic Name: Evorpacept

Drug Type: Biotech

CAS Number: 2484949-51-9

Unique Ingredient Identifier: X7K762X1IJ

Background: evorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).

Clinical Trials

PRE-I-SPY Phase I/Ib Oncology Platform Program

Phase 1

Recruiting

Conditions: Metastatic Breast Cancer
Metastatic
Hormone Receptor-positive Breast Cancer
Hormone Receptor Negative Breast Carcinoma
HER2 Low Breast Cancer
HER2 Low Breast Carcinoma
HER2-positive Breast Cancer
Metastatic Cancer
HER2-negative Breast Cancer
Solid Tumor, Adult

Interventions: Drug: ALX148
Drug: Zanidatamab
Drug: Fam-Trastuzumab Deruxtecan-Nxki
Drug: Tucatinib

First Posted Date: 2023-05-22

Last Posted Date: 2025-04-04

Lead Sponsor: QuantumLeap Healthcare Collaborative

Target Recruit Count: 124

Registration Number: NCT05868226

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

and more 4 locations

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

Phase 2

Recruiting

Conditions: Oropharynx Cancer

Interventions: Drug: Evorpacept

First Posted Date: 2023-03-28

Last Posted Date: 2025-03-26

Lead Sponsor: University of California, San Diego

Target Recruit Count: 29

Registration Number: NCT05787639

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Providence Health & Services, Portland, Oregon, United States

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Phase 1

Active, not recruiting

Conditions: Bladder Cancer
Urothelial Carcinoma

Interventions: Drug: Evorpacept
Drug: Enfortumab Vedotin

First Posted Date: 2022-09-01

Last Posted Date: 2025-05-11

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 36

Registration Number: NCT05524545

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Massachusett's General, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Phase 2

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Pembrolizumab
Drug: ALX148
Drug: Doxorubicin

First Posted Date: 2022-07-20

Last Posted Date: 2024-12-12

Lead Sponsor: Alexander B Olawaiye, MD

Target Recruit Count: 31

Registration Number: NCT05467670

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Microsatellite Stable Metastatic Colorectal Cancer

Interventions: Drug: Evorpacept (ALX148)
Drug: Cetuximab
Drug: Pembrolizumab

First Posted Date: 2021-12-22

Last Posted Date: 2025-01-13

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 48

Registration Number: NCT05167409

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Rutgers Cancer insititute, New Brunswick, New Jersey, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

and more 1 locations

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Phase 1

Active, not recruiting

Conditions: HER2-expressing Cancers

Interventions: Drug: Zanidatamab
Drug: Evorpacept

First Posted Date: 2021-08-30

Last Posted Date: 2025-05-13

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT05027139

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸
UC San Diego - Moores Cancer Center, La Jolla, California, United States

and more 8 locations

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Phase 2

Recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma

Interventions: Drug: Evorpacept (ALX148)
Drug: Trastuzumab
Drug: Ramucirumab
Drug: Paclitaxel

First Posted Date: 2021-08-12

Last Posted Date: 2024-07-31

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 450

Registration Number: NCT05002127

Locations: 🇺🇸
The Oncology Institute of Hope & Innovation, Anaheim, California, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 80 locations

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
AML, Adult

Interventions: Drug: evorpacept
Drug: venetoclax
Drug: azacitidine

First Posted Date: 2021-02-16

Last Posted Date: 2024-11-27

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 14

Registration Number: NCT04755244

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

and more 2 locations

Evorpacept (ALX148) in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: pembrolizumab
Drug: evorpacept
Drug: Cisplatin/Carboplatin; 5FU

First Posted Date: 2020-12-19

Last Posted Date: 2025-03-25

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 172

Registration Number: NCT04675333

Locations: 🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Oregon Health & Science University/ Knight Cancer Institute, Portland, Oregon, United States

and more 41 locations

Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Phase 2

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Drug: evorpacept
Drug: pembrolizumab

First Posted Date: 2020-12-19

Last Posted Date: 2025-03-25

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 189

Registration Number: NCT04675294

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, Newark, New Jersey, United States
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 49 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy